Interleukin-4, Interleukin-5, and Interleukin-13 signaling pathway (Type 2 signaling)

The Interleukin-4, Interleukin-5, and Interleukin-13 signaling pathway, collectively known as the Type 2 inflammation axis, is a critical driver of allergic and eosinophilic immune responses. Interleukin-4 (IL-4) and Interleukin-13 (IL-13) are pleiotropic cytokines that share the IL-4 receptor alpha (IL-4Rα) subunit and primarily signal through the STAT6 transcription factor to promote IgE production, goblet cell hyperplasia, and airway hyperresponsiveness (1.1.2, 1.4.2). Interleukin-5 (IL-5) is the primary cytokine responsible for the maturation, recruitment, and survival of eosinophils, signaling through the IL-5 receptor alpha (IL-5Rα) and STAT5 (1.1.3, 1.3.2). Dysregulation of this axis is central to the pathogenesis of chronic inflammatory diseases such as severe asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps (1.2.1, 1.3.1). Therapeutic strategies include monoclonal antibodies that neutralize the cytokines directly (e.g., mepolizumab for IL-5, tralokinumab for IL-13) or block their respective receptor subunits (e.g., dupilumab for IL-4Rα, benralizumab for IL-5Rα) to interrupt the inflammatory cascade (1.3.4, 1.4.3). These biologics have significantly improved clinical outcomes for patients with refractory Type 2-high conditions by selectively inhibiting the underlying molecular drivers of tissue damage and symptoms (1.3.5, 1.4.4).

Other names

Type 2 inflammation pathwayTh2 cytokine signaling axisIL-4/IL-5/IL-13 axisT2 inflammation signalingTh2-mediated immune response

Inhibition of Type 2 inflammation through monoclonal antibody-mediated neutralization of cytokines (IL-5, IL-13) or blockade of receptor subunits (IL-4Rα, IL-5Rα) to prevent downstream JAK/STAT signaling (STAT6 and STAT5).